Taken together, this work suggests that patients with schizophrenia may have much lower levels of mGluR3 stimulation in dlPFC [19], and thus may benefit from GCPII inhibition, as has been seen in rodent models [68, 69]. The gene discussed is FOLH1; the disease is schizophrenia.